Aspira Women's Health (AWH) AI Stock Analysis

• Market Cap: $2.89M
• Dividend Yield: N/A
• Average Volume (3M): 8.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: 0.31%
• EPS Growth: 44.72%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.99
• Shares Outstanding: 29,764,248
• 10 Day Avg. Volume: 877,509
• 30 Day Avg. Volume: 8,840,383
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.16
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 2900.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

Aspira Women's Health faces significant financial challenges with negative equity and ongoing cash flow issues, heavily influencing the overall score. While there is some optimism from recent corporate moves and earnings call highlights, these are insufficient to counterbalance the financial risks. Technical indicators and valuation further reflect the company's current struggles, despite potential for short-term improvements.

Aspira Women's Health Business Overview & Revenue Model

Company Description

Aspira Women's Health (AWH) is a healthcare company focused on developing and commercializing innovative diagnostic tests for women's health, particularly in the area of gynecologic disease. Its core products include proprietary risk assessment and diagnostic tests designed to aid in the early detection and management of ovarian cancer and other gynecologic conditions. Aspira's mission is to transform women's health through innovative science and a passion for improving patient outcomes.

How the Company Makes Money

Aspira Women's Health generates revenue through the sale of its proprietary diagnostic tests. These tests are primarily offered to healthcare providers, who use them to assess the risk of ovarian cancer and other gynecologic conditions in their patients. The company charges fees for each test conducted, which forms the basis of its revenue model. Additionally, Aspira may engage in partnerships with healthcare organizations, research institutions, and pharmaceutical companies, which can provide other revenue opportunities, such as collaborative research and development projects or licensing agreements. The company's earnings are significantly influenced by the adoption of its tests by healthcare professionals, reimbursement rates from insurance providers, and its ability to expand its test offerings and market reach.

Aspira Women's Health Financial Statement Overview

Summary

Aspira Women's Health shows revenue growth and improved gross profit margins, but remains unprofitable with negative equity and persistent cash flow deficits. The company's financial position is high-risk due to a high level of debt relative to assets.

Income Statement

The company has shown a slight improvement in revenues over recent years but remains unprofitable with significant negative EBIT and net income. Gross profit margin improved from 14.4% in 2020 to 59.7% in 2024, indicating cost management efficiency. However, the net profit margin remained negative due to high operating expenses.

Balance Sheet

The balance sheet reflects financial instability with negative stockholders' equity in 2023 and 2024, indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, suggesting a high-risk financial structure. The equity ratio is negative, highlighting potential insolvency risks.

Cash Flow

Operating cash flow has consistently been negative, impacting the company's ability to generate cash internally. Despite improvements in free cash flow growth rate from 2023 to 2024, the free cash flow remains negative. The operating cash flow to net income ratio is close to 1, indicating that cash outflows closely match net loss figures.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
8.96M	9.18M	9.15M	8.18M	6.81M	4.65M
	Gross Profit
5.21M	5.48M	5.26M	4.32M	3.06M	1.24M
	EBIT
-16.98M	-16.28M	-18.85M	-32.77M	-32.59M	-17.98M
	EBITDA
-16.89M	-16.28M	-16.49M	-30.87M	-32.29M	-17.72M
	Net Income Common Stockholders
-14.79M	-13.09M	-16.69M	-21.57M	-31.71M	-17.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.73M	1.77M	2.60M	13.31M	37.18M	16.63M
	Total Assets
38.73M	5.49M	6.26M	17.37M	41.08M	19.61M
	Total Debt
12.00M	2.76M	2.85M	3.83M	4.11M	5.12M
	Net Debt
-25.73M	993.00K	255.00K	-9.47M	-33.07M	-11.51M
	Total Liabilities
33.22M	8.05M	8.63M	10.64M	10.91M	9.89M
	Stockholders Equity
5.51M	-2.56M	-2.37M	6.73M	30.17M	9.72M
Cash Flow		Free Cash Flow
-14.59M	-12.15M	-15.92M	-32.42M	-27.58M	-15.22M
	Operating Cash Flow
-14.54M	-12.11M	-15.89M	-32.19M	-27.39M	-14.73M
	Investing Cash Flow
-49.00K	-37.00K	-24.00K	-232.00K	-184.00K	-490.00K
	Financing Cash Flow
11.37M	11.06M	5.22M	7.43M	48.38M	20.15M

Aspira Women's Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWH, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.19, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 27.85 is Positive, neither overbought nor oversold. The STOCH value of 38.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AWH.

Aspira Women's Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$1.04B	18.49	19.46%	―	19.07%	―
FLGT	56 Neutral	$586.45M	―	-3.76%	―	-1.99%	74.89%
EXAS	52 Neutral	$8.26B	―	-37.09%	―	10.37%	-389.98%
MYGN	51 Neutral	$737.37M	―	-17.15%	―	12.15%	61.33%
GH	49 Neutral	$5.39B	―	-4584.47%	―	31.04%	16.91%
Sector *	48 Neutral	$6.35B	1.18	-46.25%	2.67%	19.35%	1.28%
AWH	41 Neutral	$2.89M	―	587.10%	―	0.31%	44.72%

Aspira Women's Health Corporate Events

Aspira Women’s Health Secures $2M Equity Agreement

On April 4, 2025, Aspira Women’s Health entered into an equity purchase agreement with Triton Funds L.P. for up to $2 million of common stock, aiming to support its commercial activities and working capital. Additionally, Aspira appointed three new directors to its Board, bringing extensive healthcare and financial expertise, which is expected to enhance the company’s growth and development opportunities.

Spark’s Take on AWH Stock

According to Spark, TipRanks’ AI Analyst, AWH is a Neutral.

AWH’s financial instability with negative equity and persistent cash flow issues significantly weigh down the overall score. Technical analysis indicates weak momentum with potential for short-term rebound, but valuation remains a concern due to negative earnings. The earnings call and recent corporate events provide some optimism, highlighting strategic moves and achievements, but are not enough to counterbalance financial risks.

To see Spark’s full report on AWH stock, click here.

Aspira Women’s Health Signs CEO Employment Agreement

On March 27, 2025, Aspira Women’s Health Inc. announced the signing of an employment agreement with its CEO, Michael Buhle, effective March 26, 2025. The agreement outlines Mr. Buhle’s compensation package, including a base salary of $400,000, potential bonuses, stock options, and severance benefits contingent on employment terms. This strategic move is expected to strengthen the company’s leadership and potentially impact its market positioning.

Aspira Women’s Health Board Member Resigns

On March 15, 2025, Celeste Fralick announced her resignation from the Board of Directors of Aspira Women’s Health Inc., effective March 31, 2025, citing personal reasons. This resignation may impact the company’s governance and strategic direction as it seeks a replacement for the departing director.

Aspira Women’s Health Announces Leadership Changes in 2025

Aspira Women’s Health Inc. experienced leadership changes in February 2025. Dr. Sandra Milligan resigned as President for personal reasons, effective February 21, 2025, with her responsibilities being assumed by Jamie Sullivan and Todd Pappas. Additionally, Ellen Beausang was appointed as a director on February 6, 2025, bringing over 25 years of experience from roles at BioReference Health, Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics. These changes may impact the company’s strategic direction and operational management.

Aspira Women’s Health Announces Key Leadership Changes

On January 28, 2025, Aspira Women’s Health Inc. announced key leadership changes with the appointment of Michael Buhle as Chief Executive Officer and James Crawford as Vice President of Finance. Michael Buhle, who will now also serve as principal executive officer, brings over 25 years of experience in diagnostics and life science tools, having previously worked for Biovision Diagnostics and Congenica. His leadership is expected to drive the company’s commercial growth. James Crawford, who joined Aspira in 2021, will now serve as principal financial and accounting officer, bringing a decade of financial expertise to enhance the company’s fiscal strategies.